Everest Medicines, a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, appointed Mike Berry Chief Technology Officer. Berry has more than 30 years of industrial experience in advancing projects from pre-clinical development phase to commercial stage.

Berry brings extensive experience in development, scale-up and manufacturing of biopharmaceuticals, including strong knowledge of international regulatory guidelines for good manufacturing practices (GMP) and Chemistry, Manufacturing and Control (CMC). As the chief technology officer, Berry will be responsible for all CMC activities at Everest while being in charge of the operations and management of the company’s manufacturing facility in Jiashan, Zhejiang. This is an advanced facility built to meet global and Chinese GMP standards with an annual production capacity of 700 million doses of mRNA vaccines.

“Dr. Berry brings to Everest strong expertise and extensive experience in CMC and manufacturing that will help solidify our full industrial value chain,” said Rogers Yongqing Luo, CEO of Everest Medicines. “Dr. Berry will enhance our self-discovery and manufacturing capabilities and facilitate our transformation from a clinical-stage biotech to a fully integrated biopharmaceutical company.”

“I’m thrilled to join Everest to deliver important therapies that address diseases with critical unmet medical needs to patients in Greater China and other Asian countries,” said Dr. Berry. “I look forward to leveraging my expertise to develop and produce innovative drugs and vaccines at Everest through scalable, efficient and consistent manufacturing processes.”

Prior to this appointment, Berry was most recently chief technical operations officer for global operations at Clover Biopharmaceuticals, Ltd., where he was responsible for Clover’s global drug substance and drug product development and manufacturing. Before that, Berry held leadership positions at multiple U.S. and international biotech firms including Dynavax Technologies Corp., and Novartis Diagnostics and also was a CMC consultant at BioTechLogic, Inc.